IL3RA: Interleukin-3 receptor subunit alpha
A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.
Cell surface receptor for IL3 expressed on hematopoietic progenitor cells, monocytes and B-lymphocytes that controls the production and differentiation of hematopoietic progenitor cells into lineage-restricted cells.
- Drugs that act on it: 5
- With a US drug page: 2
- Type: Protein
Drugs That Act on It
Approved and clinical-stage drugs ChEMBL records for this target; those with a US approval link to their page| Pivekimab sunirine | Approved | Interleukin-3 receptor subunit alpha binding agent | Binding agent | — |
| Tagraxofusp | Approved | Interleukin-3 receptor subunit alpha binding agent | Binding agent | Boxed warning |
| CSL-360 | — | Interleukin-3 receptor subunit alpha inhibitor | Inhibitor | — |
| Flotetuzumab | — | Interleukin-3 receptor subunit alpha binding agent | Binding agent | — |
| Talacotuzumab | — | Interleukin-3 receptor subunit alpha binding agent | Binding agent | — |
Diseases Most Associated With It
Open Targets association score, 0 to 1; all associationsDrugs and mechanisms are from ChEMBL CHEMBL3712987 (CC BY-SA 3.0). Gene name, function (UniProt P26951, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets